Search results for "EXPRESSION"

showing 10 items of 5168 documents

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

2013

Estrogen receptor (ER)-negative tumors represent 20-30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition. To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environm…

Oncologygenetic associationbody-mass indexEstrogen receptorGenome-wide association studycancer riskBioinformaticssusceptibilitychromosome 1q0302 clinical medicineRisk Factorssingle nucleotide polymorphismGenotypeestrogenCooperative Behaviorcomparative studyOligonucleotide Array Sequence Analysis0303 health scienceschromosome 16q3. Good healthReceptors Estrogenpriority journal030220 oncology & carcinogenesisFemalecancer invasionsignal transductionbreast cancer; cancer invasion; cancer risk; chromosome 1; chromosome 16q; chromosome 1q; chromosome 2p; comparative study; follow up; gene locus; genetic association; genetic susceptibility; human; nucleotide sequence; priority journal; signal transduction; single nucleotide polymorphismmedicine.medical_specialtyGenotypegene locusBreast NeoplasmsSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticle03 medical and health sciencesBreast cancerbreast cancerMeta-Analysis as TopicSDG 3 - Good Health and Well-beingInternal medicineexpressionGeneticsmedicineGenetic predispositionHumansfollow upGenetic Predisposition to Diseasehumanchromosome 1gene030304 developmental biologyCase-control studyCancernucleotide sequencemedicine.diseasechromosome 2pGenetic LociCase-Control Studiescommon variantGenome-Wide Association Studygenetic susceptibilityNature Genetics
researchProduct

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

2012

Background In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed. Patients and methods We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPc…

Oncologymedicine.medical_specialtyEndoPredict geneAntineoplastic Agents HormonalReceptor ErbB-2Populationadjuvant treatmentBreast NeoplasmsKaplan-Meier EstimateAnastrozoleRisk AssessmentDisease-Free SurvivalBreast cancerInternal medicineBreast CancerexpressionAntineoplastic Combined Chemotherapy ProtocolsNitrilesmedicineHumanseducationSurvival analysisRetrospective Studieseducation.field_of_studybusiness.industryendocrine therapyAbsolute risk reductionRetrospective cohort studyHematologyOriginal ArticlesMiddle AgedTriazolesmedicine.diseasePrognosisChemotherapy regimenSurgeryTamoxifenTreatment OutcomeOncologyReceptors EstrogenChemotherapy AdjuvantPractice Guidelines as TopicFemaleBreast diseasebusinessRisk assessmentAnnals of Oncology
researchProduct

Immune cell score, PD-L1 expression and prognosis in esophageal cancer.

2021

Esophageal cancer (EC) is the ninth most common cancer worldwide and the sixth leading cause of cancer death [1]. Despite improvements in the treatment of EC, the general outcome remains poor [2–4]...

Oncologymedicine.medical_specialtyEsophageal NeoplasmsCellMEDLINEB7-H1 Antigen030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingCancer deathbusiness.industryCancerHematologyGeneral MedicineEsophageal cancermedicine.diseasePrognosismedicine.anatomical_structureOncology030220 oncology & carcinogenesisPd l1 expressionbusinessActa oncologica (Stockholm, Sweden)
researchProduct

E-Cadherin gene expression in oral cancer: Clinical and prospective data

2019

Background Low protein expression of E-cadherin in oral squamous cell carcinoma (OSCC) has been associated with clinical and histopathological traits such as metastases, recurrence, low survival and poor tumor differentiation, and it is considered a high-risk marker of malignancy. However, it is still unknown whether low expression of E-cadherin is also present at the mRNA level in OSCC cases. Objective: The aim of this study was to compare E-cadherin mRNA expression in OSCC patients and controls and to correlate the expression with clinical and prospective characteristics. Material and Methods Forty patients and 40 controls were enrolled. E-cadherin mRNA expression was evaluated by quantit…

Oncologymedicine.medical_specialtyLow proteinMalignancyMetastasis03 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineCarcinomaHumansProspective StudiesProspective cohort studyGeneral DentistryMouth neoplasmOral Medicine and PathologyE-Cadherinbusiness.industryResearchOral cancerCancer030206 dentistryCadherinsPrognosis:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellMouth NeoplasmsSurgeryGene expressionNeoplasm Recurrence LocalbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Analysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma

2019

Abstract Background Cancer stem cells (CSCs) are targets poorly recognized by the immune surveillance system given that they induce an immunosuppressive microenvironment. The aim of this work is to study the interactions between CSCs and the immune microenvironment in NSCLC. Methods Tumor cells from 8 resected NSCLC patients and 12 cell lines were established as tumorspheres enriched in CSCs and as monolayers. The gene expression of IL-4, IL-10, IL6, IL8 and LGALS-3 was analyzed by RTqPCR. Results were validated at a protein level by a sensitivity bead-based multiplex immunoassay using the Millipore kit for Luminex 100/200. The prognostic value of these factors in silico was determined in a…

Oncologymedicine.medical_specialtyLungbusiness.industryProportional hazards modelHematologymedicine.diseasemedicine.anatomical_structureOncologyGalectin-3Cancer stem cellInternal medicineGene expressionmedicineAdenocarcinomaInterleukin 8businessSurvival analysisAnnals of Oncology
researchProduct

In response: Genomic profile of breast cancer.

2015

Response to: Plun-Favreau J, Svedman C, Valentine W, Rouzier R. Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):393–94We would like to express our gratitude for th...

Oncologymedicine.medical_specialtyNational Health Programsmedia_common.quotation_subjectBreast NeoplasmsBreast cancerMammaPrintInternal medicineGratitudemedicineBiomarkers TumorHumansPharmacology (medical)Genetic TestingPrecision Medicinemedia_commonmedicine.diagnostic_testbusiness.industryHealth PolicyGene Expression ProfilingGeneral MedicineHealth Care Costsmedicine.diseaseGenomic ProfileFemaleOncotype DXbusinessExpert review of pharmacoeconomicsoutcomes research
researchProduct

The Role of Religiosity in Symptom Expression of Advanced Cancer Patients

2021

Aim: The aim of this study was to assess the religious pattern and its impact on symptom expression in patients with advanced cancer. Methods: A consecutive sample of advanced cancer patients screened at admission to palliative care. Standard epidemiological data were recorded. Patients were asked about their religious beliefs, the degree of social relationship to existing religions, the role of religion in their life, and the frequency of their prayer. The Edmonton Symptom Assessment Scale (ESAS) and Hospital Anxiety Depression scale (HADS) were assessed. Results: Two-hundred-eighty-three patients were screened. Age and gender were found to be independently correlated with religious belief…

Oncologymedicine.medical_specialtyPalliative careCONSECUTIVE SAMPLEReligiosityreligiosity.NeoplasmsInternal medicinemedicineHumansadvanced cancerIn patientKarnofsky Performance StatusAgedpalliative carebusiness.industryGeneral MedicineanxietyAdvanced cancerreligiosityReligionExpression (architecture)AnxietyFemaleSymptom Assessmentmedicine.symptombusiness
researchProduct

Identification of gene expression profiles in pancreatic ductal adenocarcinoma. Clinical implications

2013

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaHepatologybusiness.industryEndocrinology Diabetes and MetabolismInternal medicineGene expressionGastroenterologyCancer researchMedicineIdentification (biology)businessPancreatology
researchProduct

Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis?

2017

AbstractIn order to establish whether adjuvant therapy should be administered in patients with breast carcinoma, it is decisive to have as precise as possible an assessment of the risk of recurrence. In this context, gene expression — and thus gene expression signatures as well — have become a focus of attention as prognostic factors. For practical application, it is important to be able to analyze gene expression signatures in formalin-fixed, paraffin-embedded tumor tissue. Careful analytic and clinical validations and a high level of evidence (LoE) are required in order to avoid imprecise risk classification and thus potential overtreatment or undertreatment of the patients. Among the com…

Oncologymedicine.medical_specialtybusiness.industryConsensus conferenceContext (language use)Evidence-based medicinemedicine.diseaseBreast cancerInternal medicineGene expressionmedicineAdjuvant therapybusinessProspective cohort studyBreast carcinomaSenologie - Zeitschrift für Mammadiagnostik und -therapie
researchProduct

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

2020

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)

Oncologymedicine.medical_specialtydiagnosisDown-RegulationBreast NeoplasmsReal-Time Polymerase Chain ReactionArticleCatalysislcsh:ChemistryInorganic Chemistrybreast cancerBreast cancerInternal medicinemicroRNABiomarkers TumorHumansMedicineDiagnostic biomarkerCirculating MicroRNAPhysical and Theoretical Chemistryskin and connective tissue diseaseslcsh:QH301-705.5Molecular BiologyEarly Detection of CancerplasmaSpectroscopyRetrospective StudiesEarly breast cancerPlasma samplesbusiness.industryOrganic ChemistryGeneral MedicineMiddle Agedmedicine.diseaseComputer Science ApplicationsGene Expression Regulation NeoplasticMicroRNAsROC Curvelcsh:Biology (General)lcsh:QD1-999Potential biomarkersCohortbiomarkerBiomarker (medicine)FemalebusinessInternational Journal of Molecular Sciences
researchProduct